Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Cureus

Status of Registered Clinical Regulatory Trials of Non-communicable Diseases in the Pre- and Post-COVID-19 Era: A Web-Based Study

  1. 1Pharmacology & Therapeutics, Seth GS Medical College and King Edward Memorial Hospital, Mumbai, IND

Abstract

Introduction: Non-communicable diseases (NCDs) are a major global health burden and constitute the majority of all registered clinical trials. Clinical trials are vital for developing effective management strategies for NCDs. The COVID-19 pandemic significantly disrupted the conduct of clinical trials worldwide. This study aimed to compare the status of registered clinical regulatory trials for major NCDs in India and the USA before and after the pandemic.

Methodology: A retrospective, web-based analytical study was conducted. Data were collected from CTRI (Clinical Trials Registry - India) and ClinicalTrials.gov (USA) for the following NCDs: diabetes mellitus, breast cancer, asthma, hypertension, chronic obstructive pulmonary disease (COPD), ischemic heart disease, and stroke across the pre-COVID (January 2018-January 2020) and post-COVID (June 2023-June 2025) periods. Pharmaceutical industry- sponsored, interventional drug trials with regulatory approval were included. Categorical variables were analyzed by the chi-square test and Fisher's exact test with odds ratios and 95% confidence intervals. Continuous variables were analyzed using the Mann-Whitney U test. The Benjamini-Hochberg procedure was applied to control the false discovery rate for multiple comparisons, and an adjusted p-value of <0.05 was considered statistically significant.

Results: Total number of trials increased from 456 to 483 in the post-COVID period, with trials in India increasing from 95 to 141, while in the USA, they decreased slightly from 361 to 342. In India, trials for COPD increased significantly (p-value = 0.035), while trials for diabetes decreased significantly (p-value = 0.0063) in the post-COVID period. A significant decrease was seen in Phase 4 trials in the USA in the post-COVID period (p-value = 0.035). In the post-COVID period, in both countries, a significantly larger number of trials were open to recruitment and significantly fewer trials had recruitment closed. In the USA, there was a significant decrease in the number of terminated trials and trials with an unknown status. Additionally, trials in India had a significantly lower median number of study sites in the post-COVID period.

Conclusion: Overall NCD trial numbers have largely recovered post-COVID. However, certain elements were impacted; for example, in India, trials for COPD showed a significant rise, while trials for diabetes declined significantly. Phase 4 trials declined significantly in the USA. Changes were seen in recruitment status in both countries, and the median number of study sites decreased significantly in India.

Related

  1. Dietary patterns and the prevention of non-communicable diseases in aging populations: a narrative review of evidence, mechanisms, and clinical implications
    Claudia Reytor-González, Náthaly Mercedes Román-Galeano, Janeth Castano Jimenez +2
    Frontiers in Public HealthPeer-reviewedCC BY 4.0Epidemiology & public healthFrontiersCrossref
  2. Clinical trials and evaluation of AI tools in solid organ transplantation: implications for clinical care, regulatory science, and rare diseases
    Bima J. Hasjim, Annabel Koivu, Mina Sagheb +4
    NPJ Digital MedicinePeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthPMC
  3. Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries
    Faida Paison, Queen Ntumurize, Gustave Munyurangabo +11
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NDFull textGeneral medicineEurope PMC
  4. Determinants of risk factors for Non-Communicable Diseases (NCDs) in Nepal: a scoping review
    Bibha Simkhada, Kaung Suu Lwin, Rabina Dhakal +2
    BMC Public HealthPeer-reviewedCC BY 4.0Epidemiology & public healthCrossref
  5. Burden of Non-Communicable Diseases Attributable to Polygenic Risk and Its Association with Healthcare Utilization in Taiwan
    M.-Y. Shih, Y.-S. Ke, X.-Y. Chang +2
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxiv
BibTeX
@article{tripathi2026status,
  title = {{Status of Registered Clinical Regulatory Trials of Non-communicable Diseases in the Pre- and Post-COVID-19 Era: A Web-Based Study}},
  author = {Raakhi K Tripathi and Urjita R Kapadia and Avanti V Kajrolkar and Urwashi I Parmar},
  journal = {Cureus},
  year = {2026},
  month = oct,
  doi = {10.7759/cureus.117881},
  url = {https://doi.org/10.7759/cureus.117881},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Status of Registered Clinical Regulatory Trials of Non-communicable Diseases in the Pre- and Post-COVID-19 Era: A Web-Based Study
AU  - Raakhi K Tripathi
AU  - Urjita R Kapadia
AU  - Avanti V Kajrolkar
AU  - Urwashi I Parmar
PY  - 2026
DA  - 2026/10/13
JO  - Cureus
DO  - 10.7759/cureus.117881
UR  - https://doi.org/10.7759/cureus.117881
AB  - Introduction: Non-communicable diseases (NCDs) are a major global health burden and constitute the majority of all registered clinical trials. Clinical trials are vital for developing effective management strategies for NCDs. The COVID-19 pandemic significantly disrupted the conduct of clinical trials worldwide. This study aimed to compare the status of registered clinical regulatory trials for major NCDs in India and the USA before and after the pandemic.  Methodology: A retrospective, web-based analytical study was conducted. Data were collected from CTRI (Clinical Trials Registry - India) and ClinicalTrials.gov (USA) for the following NCDs: diabetes mellitus, breast cancer, asthma, hypertension, chronic obstructive pulmonary disease (COPD), ischemic heart disease, and stroke across the pre-COVID (January 2018-January 2020) and post-COVID (June 2023-June 2025) periods. Pharmaceutical industry- sponsored, interventional drug trials with regulatory approval were included. Categorical variables were analyzed by the chi-square test and Fisher's exact test with odds ratios and 95% confidence intervals. Continuous variables were analyzed using the Mann-Whitney U test. The Benjamini-Hochberg procedure was applied to control the false discovery rate for multiple comparisons, and an adjusted p-value of <0.05 was considered statistically significant.  Results: Total number of trials increased from 456 to 483 in the post-COVID period, with trials in India increasing from 95 to 141, while in the USA, they decreased slightly from 361 to 342. In India, trials for COPD increased significantly (p-value = 0.035), while trials for diabetes decreased significantly (p-value = 0.0063) in the post-COVID period. A significant decrease was seen in Phase 4 trials in the USA in the post-COVID period (p-value = 0.035). In the post-COVID period, in both countries, a significantly larger number of trials were open to recruitment and significantly fewer trials had recruitment closed. In the USA, there was a significant decrease in the number of terminated trials and trials with an unknown status. Additionally, trials in India had a significantly lower median number of study sites in the post-COVID period.  Conclusion: Overall NCD trial numbers have largely recovered post-COVID. However, certain elements were impacted; for example, in India, trials for COPD showed a significant rise, while trials for diabetes declined significantly. Phase 4 trials declined significantly in the USA. Changes were seen in recruitment status in both countries, and the median number of study sites decreased significantly in India.
SN  - 2168-8184
ER  -